Phase 2 Trial of FLP ( 5-FU , Leucovorin , Cisplatin ) Combination Chemotherapy for Advanced Gastric Cancer.
- Author:
Young Iee PARK
;
Moon Hee LEE
;
Sung Woo HAN
;
Woo Jung PARK
;
Dong Gyu KIM
;
Jin LEE
;
Jin Seok AHN
;
Jung Ae RHEE
;
In Sook WOO
;
Young Suk PARK
- Publication Type:Original Article
- Keywords:
FLP combination chemotherapy;
Advanced stomach cancer
- MeSH:
Anemia;
Cisplatin*;
Diarrhea;
Drug Therapy;
Drug Therapy, Combination*;
Female;
Fluorouracil*;
Follow-Up Studies;
Gastrointestinal Neoplasms;
Humans;
Korea;
Leucovorin*;
Leukopenia;
Male;
Nausea;
Peripheral Nervous System Diseases;
Sepsis;
Stomach Neoplasms*;
Stomatitis;
Survival Rate;
Vomiting
- From:Journal of the Korean Cancer Association
1998;30(1):55-62
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Advanced gastric cancer, the most common malignancy in Korea is a kind of systemic disease. At dignosis, 50~80% of patients have systemic cancer. Therefore, the most patients require systemic chemotherapy. Cisplatin and 5-FU have been suggested to be active in the treatment of gastric cancer, a high response rate was observered with a combination of 5-FU infusion and cisplatin, and the biochemical modulation of 5-FU by leucovorin has been demonstrated to enhance the activity of 5-FU in gastrointestinal tract cancer. MATERIALS AND METHODS: The patients with advanced gastric cancer whose disease had relapsed or unresectable were treated with 5-FU(800 mg/m2 12 hr IV infusion, D 1~5), leucovorin(20 mg/m2 IV, D 1~5, max. 30 mg), cisplatin(100 mg/m2 15min IV dripping, D1). The cycles of treatment were repeated at 3-weeks intervals. RESULTS: Between Sep. 1994 and Aug. 1996, previously untreated 44 patients(39 eligible patients) were admitted to this study, the median age was 55 years(range 17~73) and male to female ratio was 20:19. The rate of complete remission was 5%(2/39), the rate of partial remission was 21%(8/39). The median-response duration was 26 weeks(5+~38+ ). The median-time to progression was 25 weeks(4+~62+). The range of overall survival time was from 4 to 62+ weeks. 24 weeks survival rate was 71.5% but the median survival time was not reached. The leukopenia and anemia were the main hematologic toxicities. Non-hematologic side effects were nausea, vomiting, diarrhea, stomatitis, peripheral neuropathy. These toxicities were observed commnonly, but tolerable. Two treatment-related deaths were associated with sepsis. CONCLUSION: Based on these results, FLP combination chemotherapy seems to be a moderate efficacy for advanced gastric cancer with tolerable toxicities. To confirm the efficacy further, the long-term follow up and a large scale of clinical studies are needed.
